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p53 mutations and loss of heterozygosity have been commonly associated with oesophageal adenocarcinoma. In this investigation,
the p53 status of a Welsh population of Barrett’s-associated oesophageal adenocarcinomas were fully characterised at the gene
sequence, chromosomal, mRNA and protein levels. In total, 31 tumours were examined for p53 gene sequence mutations using
RFLP with sequencing, allelic loss of the gene was characterised by FISH, mRNA expression by p53 pathway signalling arrays and
protein levels by p53 immunohistochemistry. In all, 9.6% of adenocarcinomas harboured p53 mutations, 24% displayed p53 allelic loss
and 83% exhibited p53 protein accumulation. Point mutations and deletions of the gene did not coexist within the same samples. All
samples containing p53 mutations also displayed positive immunostaining; however; in the majority of cases, p53 protein
accumulation developed in the absence of mutations. The gene expression analysis demonstrated no differences in p53 and mdm-2
transcription levels between the p53 immunonegative and immunopositive samples, indicating other mechanisms underlie the
proteins’ overexpression. In conclusion, p53 mutations and deletions do not appear to be frequent events in oesophageal
adenocarcinomas; however, abnormal accumulation of the protein is present in a vast majority of cases. P53 gene mutations are not
the primary cause of protein overexpression – an alternative mechanism is responsible for the positive p53 immunohistochemistry
detected.
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The incidence of oesophageal adenocarcinoma has risen at a
greater rate than any other malignancy in the USA and most
European regions, currently varying from one in 146 to one in 285
cases/patient/year (Drewitz et al, 1997; O’Connor et al, 1999;
Botterweck et al, 2000; Nilsson et al, 2000; Conio et al, 2001).
Adenocarcinoma of the oesophagus almost always arises as a
consequence of the neoplastic progression of Barrett’s oesophagus
and has a poor prognosis, with 5-year survival rates of only 10%
(Farrow and Vaughan, 1996). It is seldom found early enough for
curative treatment, thus 93% of diagnosed patients die due to early
vascular invasion and metastasis, making this a very aggressive
malignancy (Neshat et al, 1994).
Barrett’s oesophagus and its associated oesophageal adenocar-
cinoma show p53 alterations like many other malignant condi-
tions, with allelic loss and mutations being the most commonly
documented means of gene inactivation. Loss of heterozygosity
(LOH) of the p53 locus has been found in 75–80% of oesophageal
adenocarcinomas (Gleeson et al, 1998; Morgan et al, 1998; Wu et al,
1998), as well as in 79% of high-grade dysplasia (HGD), 42% of
low-grade dysplasia (LGD) and in 14% of Barrett’s metaplastic
tissue (Wu et al, 1998). Hence, suggesting LOH of the p53 locus is
an important change that develops early during Barrett’s
neoplastic progression.
p53 mutations frequently arise in both Barrett’s oesophagus and
oesophageal adenocarcinoma, occurring in 40–88% of cancers
(Hamelin et al, 1994; Gleeson et al, 1995, 1998; Soslow et al, 1999)
and 30–66% of Barrett’s epithelium with mild or no dysplasia
(Hamelin et al, 1994; Neshat et al, 1994). Between 50 and 80% of
documented Barrett’s p53 mutations are mis-sense (GC-AT base
transitions at CpG islands) and 10–50% are nonsense (Huang et al,
1993; Gleeson et al, 1998). In both HGD and adenocarcinoma,
mutations have been found between codons 152–306, but the
most common alterations are transitions, 53% of which occur at
the CpG dinucleotide hotspot codons 175, 196, 213, 245, 248, 273
and 282 (www.iarc.fr). Mutations at these sites disrupt p53s
ability to bind DNA and regulate stress response genes. The
result is an accumulation of errors in the genome, which is
passed onto daughter cells thus aiding neoplastic progression.
This may explain why Barrett’s patients with p53 mutations
have more advanced tumours, significantly worse prognosis and
are on average 15 years younger than those without such
alterations (Ireland et al, 2000). As these mutated p53 molecules
have an altered conformation and can no longer form a complex
with Mdm2, they are not degraded. P53 protein accumulation
has been detected by immunohistochemistry in 7% of LGD,
30–60% of HGD and 45–85% of adenocarcinoma (with most
reports closer to the 80% level), but not in metaplastic Barrett’s
epithelia (Moskaluk et al, 1996; Coggi et al, 1997; Rioux-Leclercq
et al, 1999). Revised 25 June 2003; accepted 28 July 2003
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inactivate wild-type p53 molecules, but this is not the case for all
p53 mutations and a weak p53 response can still prevail when only
one allele is defective. Complete loss of wild-type p53 protein
within a cell rarely occurs as a result of homozygous deletions or a
double mutation, the second allele is usually inactivated by an
alternate mechanism to the first. When Barrett’s metaplastic tissue
was examined, it was found that 95–100% of cases with 17p LOH
also had p53 gene mutations (Gleeson et al, 1998; Barrett et al,
1999), while patients without LOH of the gene still carried a
mutated p53 allele (Dolan et al, 1999). This suggests a mutation in
one allele of the p53 gene probably occurs first followed by allelic
loss of the second during neoplastic progression, resulting in a p53
null phenotype that can promote tumorigenesis in Barrett’s
oesophagus.
Indirect inactivation of p53 in oesophageal adenocarcinoma also
occurs as a result of mdm2 overexpression, which has been found
in 55% of adenocarcinomas (Soslow et al, 1999). The primary
function of mdm2 is inhibition of p53 activity by directly
interacting with its specific DNA binding/transactivation sites
(Ashcroft and Vousden, 1999). Although mdm2 is also involved in
promoting p53 degradation by transporting it from the nucleus to
cytoplasm, its overexpression in human tumours maintains
endogenous p53 in a nonfunctional state (Chen et al, 1996). It is
therefore interesting to note that mdm2 overexpression in
oesophageal adenocarcinomas only occurs in patients without
p53 mutations (Soslow et al, 1999). Hence, the resultant
stabilisation of wild-type p53 protein may be an alternative
mechanism for loss of its protective functioning.
In this study, the p53 status in a Welsh population of
oesophageal adenocarcinomas was characterised at both the
gene and protein levels by looking for gene sequence mutations,
allelic deletions, gene expression alterations and accumulation of
the p53 protein. Examination of the interactions between the
differing p53 alterations investigated provide an insight into
the frequency and underlying mechanisms of p53 inactivation
that are selected for during Barrett’s associated neoplastic
progression.
MATERIALS AND METHODS
Patient samples
In all, 31 cases of Barrett’s adenocarcinoma were retrieved from
the archives of the Departments of Pathology in Singleton and
Morriston Hospitals (Swansea, UK). The male:female ratio was
4:1 with an age range of 42–95 years (median of 66.5 years). The
samples had been formalin-fixed then paraffin-embedded and
included both biopsies and surgical resections. In total 8 4mm
and 1 20mm sections per patient sample were cut:
  1 4mm section was stained with haematoxylin & eosin to
facilitate accurate identification of the malignant regions within
the sections (by APG and VS).
  5 4mm sections on glass slides were used for DNA extraction
(gene mutation analysis).
  1 4mm section on an Apes slide was used for investigation
using fluorescence in situ hybridisation (FISH; for gene dosage
examination).
  1 4mm section also on an Apes slide was for immunohisto-
chemical analysis (protein level investigation).
  1 20mm section on a glass slide was required for total RNA
extraction (gene expression analysis).
Mutation analysis
To enrich for tumour cells, DNA was only extracted from the
specific neoplastic areas within the 5 4mm sections/patient. The
samples were dewaxed and the DNA extraction was performed
utilising a Stratagene Kit (Amsterdam, The Netherlands).
As the final concentration of DNA extracted was low, nested
PCR was used to amplify p53 exons 5–8 from each sample (Kusser
et al, 1993; Yoshida et al, 2003). The whole region between exons 5
and 8 (inclusive) was amplified initially and then subsequently
used as the template for amplification of each individual exon.
Table 1 details the PCR primers and their respective annealing
temperatures utilised with standard PCR procedures (Jenkins et al,
2003; Yoshida et al, 2003).
Restriction fragment length polymorphism (RFLP) was em-
ployed to rapidly screen for mutations within p53 hotspot codons.
The normal sequence at codons 175 (exon 5), 213 (exon 6) and
both 248 (exon 7) and 282 (exon 8) were digested with Hha1, Taq1
and Msp1, respectively. Bst 71I & Hpy CH4V digested GGC to AGC
& CGT to CAT mutants at codons 245 (exon 7) and 273 (exon 8),
respectively. To characterise hotspot mutations detected by RFLP
and identify mutations that lay outside the codons examined, the
p53 exons 5–8 from each sample were sequenced in both forward
and reverse directions. The primers used for sequencing are
detailed in Table 1 and any mutation detected was verified by
sequencing a second PCR product to rule out artefacts introduced
by Taq error.
Immunohistochemistry
One paraffin-embedded section from each of the 31 oesophageal
adenocarcinomas was processed, according to the standard ABC
immunoperoxidase procedure for p53 immunohistochemical
analysis and using mouse anti-human monoclonal antibody DO-
7 (Novocastra Laboratories, Peterborough, UK). The antibody was
diluted 1:50 in PBS and was applied as previously described
(Freedman and Maddox, 2001). The immunostaining intensity was
graded as: 0, immunonegative; 1, weak; 2, moderate; 3, strong
positivity.
FISH
Slides were dewaxed in three 10-min xylene washes, dehydrated in
two 5-min 100% ethanol washes and then allowed to air dry. Tissue
sections were permeabilised using a Paraffin Pre-treatment
Reagent Kit (Vysis, Surrey, UK) according to the manufacturers’
instructions; however, the protease solution digestion was
extended to 25min.
Table 1 Primer sequences and their respective annealing temperatures for both p53 amplification and nucleotide sequencing
Region for amplification Primer annealing temperature (1C) Forward primer sequence Reverse primer sequence
Exons 5–8 59 CACTTGTGCCCTGACTTTCAAC AAAAGTGAATCTGAGGCATAAC
Exon 5 60 CCGCGCCATGGCCATCT GCGCTCATGGTGGGGG
Exon 6 65 GTCCCCAGGCCTCTGATTCCTC TAACCCCTCCTCCCAGAGACCCCAG
Exon 7 60 CTTGCCACAGGTCTCCCCAA AGGGGTCAGCGGCAAGCAGA
Outer exon 8 60 GGACAGGTAGGACCTGATTTCC AAAAGTGAATCTGAGGCATAAC
Inner exon 8 60 ACTGCCTCTTGCTTCTCTTTTCCTATCC CTTGGTCTCCTCCACCGCTTCTTG
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UK) were subsequently cohybridised onto to the pretreated
sections from each sample as previously described (Doak et al,
2003). In all, 200 nuclei/slide were scored for the loss or gain of p53
and chromosome 8 signals. Nuclei that were obviously damaged or
overlapping were excluded from the analysis, and as two probes
were used in the hybridisation, nuclei containing a single signal
from both probes were also omitted to minimise error caused
primarily by signal truncation due to the sectioning procedure. To
establish the background hybridisation variation, the probes were
applied to and scored on five control sections consisting of normal
squamous oesophageal epithelium. The cutoff levels for definition
of deletions/amplifications were defined as the mean percentage of
cells þ3 s.d. of the signal losses/gains displayed in the control
samples evaluated (Debiec-Rychter et al, 2001; Doak et al, 2003).
No amplification of either probe was seen in the controls, but
signal losses were found in 4.5–9.5% and 5.5–10.5% of cells scored
per control sample for CEP 8 and LSI p53, respectively.
Consequently, signal losses had to be present in more than 13.9
and 13.7% of cells for CEP8 and LSI p53 respectively to be
considered a significant deletion.
p53 pathway gene expression patterns
The total RNA was extracted from 2 fresh biopsies taken within
an area of normal squamous cell epithelium from 3 patients using
the TRIspin method (Reno et al, 1997). The Paraffin Block RNA
Isolation Kit (Ambion, Cambridgshire, UK) was also used to
extract the total RNA from 10 20mm paraffin-embedded
oesophageal adenocarcinoma sections. The archival samples
selected originated from all five of the patients that had p53
immunonegative tumours, and the five that displayed the strongest
p53 protein accumulation (in the immunohistochemical analysis).
The isolated RNAs from the immunopositive samples were pooled
together, as were the RNA extracted from the five immunonegative
tissues, to collect a sufficient quantity for the subsequent gene
expression analysis. Pooling the samples increased their total
volume to 50ml; hence, to further concentrate them, the RNA was
precipitated and resuspended in 10ml sterile RNase-free water.
The three RNA samples (immunopositive and immunonegative
adenocarcinomas and normal squamous) were applied to the
GEArray Q Series Human p53 Signalling Pathway Gene Array
(SuperArray, Cambridge, UK), according to the manufacturers’
instructions. A total of 96 genes involved in p53 upstream and
downstream signalling, in addition to the p53 family itself, were
represented on the arrays utilised.
RESULTS
The integrated results for the p53 mutation, deletion and
immunohistochemical analyses are detailed in Table 2, thus
demonstrating the p53 status in each oesophageal adenocarcinoma
examined.
p53 mutation analysis
Mutations in the p53 gene were found in 9.6% (3/31) of
oesophageal adenocarcinomas. Four base substitutions were
identified in total (listed in Table 2): samples 21 and 29 harboured
Table 2 p53 status in oesophageal adenocarcinoma
Mutations in p53
Sample Exon Codon Base change Amino-acid substitution P53 IHC
a p53 deletion (% of cells)
1 +
2 +++
3 0
4 +++
5 +++
6 +++
7 7 245 GGC-GAC Gly-Asp ++
7 247 AAC-AAT Asn-Asn
8 NA NA
9 ++
10 +++
11 +++
12 +++
13 ++ 17.5
14 +++ 14.5
15 +++ 24.0
16 0
17 0
18 0 21.5
19 +++
20 +++ 14.0
21 7 249 AGG-GGG Arg-Gly +++
22 +++
23 + 14.0
24 +++
26 +++
28 0 14.0
29 6 214 CAT-CGT His-Arg +++
30 +++
31 +++
32 +++
33 NA NA
NA indicates samples that were unavailable for the immunohistochemical and FISH analyses; all blank cells indicate no p53 mutations or deletions (above the cutoff percentage)
were found in the samples.
ap53 immunohistochemistry: 0¼immuno-negative; +¼weak; ++¼moderate; +++¼strong p53 staining.
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contained two mutations, one at codon 245 and a second silent
mutation at codon 247. Three mutations were found in exon 7 and
one in exon 6 with all involving a base transition. Of the
nonsynonymous mis-sense mutations, two were an A-G transi-
tion and the third was G-A at a CpG site.
p53 allelic loss
The loss of one p53 allele detected by FISH at a level higher than
the defined cutoff was found in 24% (7/29) of oesophageal
adenocarcinomas. The proportion of cells within each sample
containing this aberration ranged from 14 to 24% (Table 2). The
cells bearing p53 deletions were generally clustered together (as
illustrated in Figure 1) rather than scattered throughout the
tumour, suggesting clonal expansion.
Immunohistochemical p53 overexpression
Accumulation of the p53 protein was detected in 83% (24/29) of
the oesophageal adenocarcinomas examined. Weak-to-moderate
nuclear p53 immunostaining was observed in five samples, while
the remaining 19 samples all had strong immunostaining for the
protein (Table 2).
Relationship between P53 mutation, deletion and protein
overexpression in oesophageal adenocarcinoma
Immunopositivity for the p53 protein was detected far more
frequently than mutation or deletion of the gene. Only three out of
24 cases immunopositive for p53 contained a mutated gene. Two
out of the three samples with mutations exhibited strong p53
staining, but the sample harbouring two mutations in the p53 gene
(number 7) only scored moderately for p53 protein accumulation.
Oesophageal adenocarcinomas with p53 mutations did not
contain gene deletions in addition. Notably, allelic loss of p53 was
associated with 40% (two out of five) of the p53 immunonegative
samples.
p53 pathway gene expression patterns
The arrays employed harboured two spots for each of five
constitutively expressed control genes, which displayed strong
hybridisation signals on all arrays utilised. Hence, validating the
adequate quality of RNA extracted from both fresh and archival
material. Figure 2 displays two examples: the RPL13A and
cyclophilin A control genes.
When comparing gene expression patterns in the adenocarci-
nomas (both immunonegative and immunopositive) to the normal
squamous tissues, the most striking difference observed was the
loss of p16 gene expression in both cancer arrays (Figure 2). A
slight downregulation of the MAP2K and BBC3 genes was also
noted in both the adenocarcinoma arrays when compared to the
normal squamous RNA gene expression pattern. However, due to
the limited amount of RNA available for the cancers, these
preliminary observations could not be quantitated.
For the genes examined on the p53 array, there were no distinct
differences in the gene expression patterns between the immuno-
positive vs immunonegative oesophageal adenocarcinomas. The
preliminary data indicated there was a slight downregulation of the
HSP70 and GADD45A genes; however, no further RNA was
available to verify this observation by quantitative PCR. It was also
notable that no increase in expression of the p53 and mdm-2 genes
Figure 1 FISH images displaying p53 (red probe) deletions in a cluster of cells within an oesophageal adenocarcinoma. The green signal represents the
centromeric region of chromosome 8. Coupled maps of the images indicate the cells demonstrating loss of a single copy of p53.
Cyclophilin A control
RPL13A control 
Squamous1 
mdm-2
p16 
p53 
Negative2 Positive3 
Figure 2 Human p53 Signalling Pathway Gene Array signals obtained for
a selection of genes when hybridised with RNA extracted from:
1¼oesophageal squamous epithelial biopsies; 2¼p53 immunonegative;
3¼p53 immunopositive paraffin-embedded oesophageal adenocarcinoma
sections.
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strong p53 protein accumulation (Figure 2).
DISCUSSION
The reported frequencies of p53 gene mutations, deletions and p53
immunopositivity vary quite considerably for oesophageal adeno-
carcinoma. Consequently, in this investigation the aim was to
completely characterise the p53 status in a Welsh population. This
was performed at the gene sequence, chromosomal, mRNA and
protein levels.
Only 10% of the oesophageal adenocarcinomas examined were
found to contain a mutation within the p53 gene. Just one of these
was identified within a hotspot (codon 245), while those remaining
were detected directly adjacent to the hotspot codons. The
mutation frequency determined in this investigation was con-
siderably lower than reported in the general literature; never-
theless, two other studies documented comparably lower p53
mutation frequencies of 8 and 12% (also at codon 245) (Casson
et al, 1991; Gonzalez et al, 1997). It is unlikely that just examining
exons 5–8 missed many mutations, as 490% of the mutations
documented in a wide range of tumours are found within this
region (Hamelin et al, 1994; www.iarc.fr). This discrepancy could
be due to several factors. Differing methodologies may be
responsible, for example, PCR-based techniques alone may
introduce artefacts (due to errors introduced by the polymerase
enzyme) if they are not confirmed by a second independent
experiment. Additionally, RFLP and sequencing will only identify
mutations if they are present in over 10% of cells within the
tumour. If mutations were present in a very small subclone of cells,
then they may not have been detected with the techniques
employed in this study. Hence, investigations using more sensitive
molecular techniques may result in the identification of rare p53
mutations (Jenkins et al, 2003). There are also several investiga-
tions that have used immunohistochemistry as a direct indicator of
p53 gene mutations (Hardwick et al, 1994; Rioux-Leclercq et al,
1999; Younes et al, 2000), but it can be clearly seen by the results in
this and other studies that p53 mutations alone are not responsible
for abnormal accumulation of the protein (Battifora, 1994; Coggi
et al, 1997; Soslow et al, 1999). Differing sample sizes and types
(i.e. fresh tissues vs paraffin-embedded archival samples) may
cause variability, as would different populations and their habits
(e.g. ethnicity/diets/proportion of smokers/alcohol intake). Finally,
variation in the statistical methods applied may provide another
source of discord.
Several investigations have focused on the frequency of p53
allelic loss in oesophageal adenocarcinoma, with LOH analysis
(Gleeson et al, 1998; Morgan et al, 1998; Dolan et al, 1999). This
technique involves the detection of gene dosage imbalances by
PCR-based microsatellite genotyping; however, there are a number
of methodological difficulties (Tomlinson et al, 2002). Tumour
samples not only contain contaminating normal cells, but are also
genetically heterogeneous; therefore, a deletion would have to be
present in a substantial number of cells to be detected by LOH
analysis. In addition, most tumours are aneuploid and consider-
able LOH frequency differences have been detected between flow-
sorted aneuploid and diploid cells (Bonsing et al, 2000). LOH-
based studies therefore tend to be inconsistent, particularly as
definitions for LOH thresholds are variable (Tomlinson et al,
2002). In contrast, FISH involves direct visualisation of the nuclear
DNA content on a single-cell basis. The technique is not as high
throughput as LOH analysis, but it is more sensitive and can
provide additional information, such as the actual position and
proportion of cells with allelic deletions within the tumour. FISH
was therefore the technique of choice in the present study.
Allelic loss of p53 was consequently detected in 24% of
oesophageal adenocarcinomas, but in each of these samples only
14–24% of cells displayed the aberration. As tumours are clonally
derived (Nowell, 1976), it would be expected that an abnormality
responsible for expansion of the neoplasm would be present
throughout – this was not observed in these samples. However, the
cells with loss of one p53 allele were always clustered, suggesting
they were the result of a subclone that had arisen within the
tumours during development and thus did not arise from the
original progenitor cells. If we had performed LOH analysis, the
clustered pattern of p53 loss would never have been identified, and
it is likely that p53 deletions would not have been detected in any
of our samples, as at least 75% of cells would have retained both
alleles. The threshold that defines significant signal loss may
therefore not have been reached. Of additional interest was the fact
that p53 gene mutations and deletions did not coexist within any of
the samples examined, further suggesting complete p53 inactiva-
tion is not an important event in the development of oesophageal
adenocarcinoma.
The most important finding in this investigation was that while
83% (24 out of 29) of the adenocarcinomas were immunopositive
for p53 protein, only 9.6% (three out of 31) contained a gene
mutation. The remaining 21 cases with p53 immunoreactivity all
had a normal p53 sequence between exons 5–8. It is possible that
mutations may be present in the exons that were not evaluated in
this study. However, this would be unlikely to account for the high
level of p53 protein positivity detected, as very few mutations have
been detected outside of exons 5–8 (www.iarc.fr); therefore,
indicating nonmutational p53 protein stabilisation is responsible.
A recent publication has demonstrated p53 immunostaining in a
variety of normal tissues when using the D07 antibody (Pillai et al,
2003), but in the present study several cases were distinctly p53
immunonegative; therefore, suggesting all the immunopositive
cases were due to abnormal protein accumulation. Several other
causes for p53 protein accumulation exist: (1) overexpression of
the p53 gene; (2) stabilisation of p53 via overexpression of mdm-2
or other pathways involved in the control of p53 stability; (3)
dysfunctional p53 degradation pathway; (4) abnormal post-
transcriptional/translational p53 modifications. To investigate
these possibilities, RNA extracted from samples that were
immunonegative and those displaying very strong positivity for
p53 protein were applied to arrays spotted with genes involved in
p53 upstream and downstream signalling pathways. Five RNA
samples from each group were pooled, hence genes altered in
individual tumours would not have been detected. The overall
expression pattern was examined, as this would indicate the
common changes present in all the tumours (from the immuno-
positive and immunonegative groups) that were responsible for
accumulation of the p53 protein.
The transcripts examined in the present study were expressed at
similar levels in both the p53 protein positive and negative
samples; in addition, there was no difference in the expression
levels of the p53 and mdm-2 genes (Figure 2). Although this
expression analysis did not indicate the possible underlying cause
for the protein accumulation, it did rule out overexpression of the
p53 and mdm-2 genes as possibilities, indicating some other
mechanism must be involved.
The gene expression patterns between the normal squamous
epithelium and oesophageal adenocarcinoma were also compared.
Expression of the p16 tumour suppressor gene was considerably
down regulated; hence, was probably a common event in all of the
tumours, which is in agreement with the literature. LOH at the p16
locus and methylation of the genes’ promoter region have been
frequently identified in both premalignant Barrett’s epithelium and
oesophageal adenocarcinoma – events that have been strongly
associated with loss of p16 expression (Wong et al, 1997; Klump
et al, 1998; Bian et al, 2002). In addition, preliminary observations
indicated the MAP2K and BBC3 genes were slightly down-
regulated. Mitogen-activated protein kinase kinase (MAP2K) is a
member of the MAP kinase family, and mediates a cellular
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kines through signal transduction cascades. bcl2-binding compo-
nent 3 (BBC3) is a mediator of p53-associated apoptosis and
although its expression in human malignancies is relatively
unexplored, suppression might be expected to enhance the survival
of neoplastic cells (Han et al, 2001). As the RNA samples examined
were pooled, it is possible that the expression of these genes were
lost in a single case and not in the others, hence resulting in a
slight overall reduction. Further gene expression investigations on
individual oesophageal adenocarcinomas are therefore warranted.
Paraffin-embedded tissues are an invaluable source of material
for molecular investigations. However, reliable extraction of RNA
from archival samples is problematic. The most successful RNA
extraction method to date was utilised in the present study (Lewis
et al, 2001), but the yields were low and the RNA was without
doubt degraded. Despite the compromised nature of the RNA
obtained upon extraction from paraffin-embedded sections, high-
quality data has been previously obtained upon hybridisation to
microarrays, with quantitative detection of up to 80% of genes
when compared to fresh-frozen samples (Lewis et al, 2001).
However, this is quite controversial and the use of RNA recovered
from archival tissue samples for array analysis requires extensive
validation. It is therefore important to note that the information
obtained in the present gene expression study is preliminary data.
Distinct gene expression differences, such as the loss of p16 in the
tumour samples demonstrate reliable alterations, but the results
are more debatable where only slight differences were seen.
Further investigations are thus also required to assess both the
frequency and biological significance of the potential gene
expression alterations identified here.
To summarise, this investigation has demonstrated that 9.6, 24
and 83% of oesophageal adenocarcinomas contained p53 gene
mutations, deletions and p53 protein immunopositivity, respec-
tively. Mutations did not coexist with deletions of the gene and
although all cases with a p53 mutation were immunopositive, most
immunopositive cases had no demonstrable p53 mutation. Thus,
immunohistochemistry is a poor indicator of p53 gene mutations
in oesophageal adenocarcinoma. Although overexpression of the
mdm-2 and p53 genes can be ruled out as possible causes, the
underlying mechanism responsible for the accumulation of the
protein has yet to be determined and requires further investiga-
tion.
ACKNOWLEDGEMENTS
We thank Mrs Sue Fielding and Mr Chris Bowden for their
technical assistance with the sequencing and immunohistochem-
istry. SH Doak was funded by a Tenovus Studentship.
REFERENCES
Ashcroft M, Vousden KH (1999) Regulation of p53 stability. Oncogene 18:
7637–7643
Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG,
Rabinovitch PS, Reid BJ (1999) Evolution of neoplastic cell lineages in
Barrett oesophagus. Nat Genet 22: 106–109
Battifora H (1994) p53 immunohistochemistry: a word of caution. Hum
Pathol 25: 435–437
Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J (2002) p16
inactivation by methylation of the CDKN2A promoter occurs early
during neoplastic progression in Barrett’s esophagus. Gastroenterology
122: 1113–1121
Bonsing BA, Corver WE, Fleuren GJ, Cleton-Jansen AM, Devilee P,
Cornelisse CJ (2000) Allelotype analysis of flow-sorted breast cancer cells
demonstrates genetically related diploid and aneuploid subpopulations
in primary tumors and lymph node metastases. Genes Chromosomes
Cancer 282: 173–183
Botterweck AAM, Schouten LJ, Volovics A, Dorant E, van den Brant PA
(2000) Trends in incidence of adenocarcinoma of the oesophagus and
gastric cardia in ten European countries. Int J Epidemiol 29: 645–654
Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA (1991)
p53 gene mutations in Barrett’s epithelium and esophageal cancer.
Cancer Res 51: 4495–4499
Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and
apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol
16: 2445–2452
Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero
S, Piazza M, Blandamura S, Segalin A, Bonavina L, Peracchia A (1997)
p53 protein accumulation and p53 gene mutation in esophageal
carcinoma. Cancer 79: 425–432
Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ,
Zinsmeister AR, Melton III LJ, Locke III GR (2001) Secular trends in the
epidemiology and outcome of Barrett’s oesophagus in Olmsted County,
Minnesota. Gut 48: 304–309
Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M
(2001) Chromosomal aberrations in malignant gastrointestinal stromal
tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet
128: 24–30
Doak SH, Jenkins GJS, Parry EM, D’Souza FR, Griffiths AP, Toffazal N,
Shah V, Baxter JN, Parry JM (2003) Chromosome 4 hyperploidy
represents an early genetic aberration in pre-malignant Barrett’s
oesophagus. Gut 52: 623–629
Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK (1999) LOH at the
sites of the DCC, APC and TP53 tumour suppressor genes occurs in
Barrett’s metaplasia and dysplasia adjacent to adenocarcinoma of the
esophagus. Hum Pathol 30: 1508–1514
Drewitz DJ, Sampliner RE, Garewal HS (1997) The incidence of
adenocarcinoma in Barrett’s esophagus: a prospective study of 170
patients followed 4.8 years. Am J Gastroenterol 92: 212–215
Farrow DC, Vaughan TL (1996) Determinants of survival following the
diagnosis of esophageal adenocarcinoma (United States). Cancer Causes
Control 7: 322–327
Freedman LJ, Maddox MT (2001) A comparison of anti-biotin and
biotinylated anti-avidin double-bridge and biotinylated tyramide im-
munohistochemical amplification. J Neurosci Methods 112: 43–49
Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SEH (1995) Base
transitions at CpG dinucleotides in the p53 gene are common in
esophageal adenocarcinoma. Cancer Res 55: 3406–3411
Gleeson CM, Sloan JM, McManus DT, Maxwell P, Arthur K, McGuigan JA,
Ritchie AJ, Russell SEH (1998) Comparison of p53 and DNA content
abnormalities in adenocarcinoma of the oesophagus and gastric cardia.
Br J Cancer 77: 277–286
Gonzalez MV, Artimez ML, Rodrigo L, LopezLarrea C, Menendez MJ,
Alvarez V, Perez R, Fresno MF, Perez MJ, Sampedro A, Coto E (1997)
Mutation analysis of the p53, APC, and p16 genes in the
Barrett’s oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 50:
212–217
Hamelin R, Flejou J-F, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas
G (1994) TP53 gene mutation and p53 protein immunoreactivity in
malignant and premalignant Barrett’s esophagus. Gastroenterology 107:
1012–1018
Han JW, Flemington C, Houghton AB, Gu ZM, Zambetti GP, Lutz RJ, Zhu
L, Chittenden T (2001) Expression of bbc3, a pro-apoptotic BH3-only
gene, is regulated by diverse cell death and survival signals. Proc Natl
Acad Sci USA 98: 11318–11323
Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D
(1994) Adenocarcinoma arising in Barrett’s oesophagus: evidence for the
participation of p53 dysfunction in the dysplasia/carcinoma sequence.
Gut 35: 764–768
Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, McDaniel T,
Boynton RF, Zou ZQ (1993) Altered messenger-RNA and unique
mutational profiles of p53 and RB in human esophageal carcinomas.
Cancer Res 53: 1889–1894
Characterisation of p53 status in oesophageal adenocarcinoma
SH Doak et al
1734
British Journal of Cancer (2003) 89(9), 1729–1735 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yIreland AP, Shibata DK, Chandrasoma P, Lord RVN, Peters JH, DeMeester
TR (2000) Clinical significance of p53 mutations in adenocarcinoma of
the esophagus and cardia. Ann Surg 231: 179–187
Jenkins GJS, Doak SH, Griffiths, AP, Toffazal N, Shah V, Baxter JN, Parry
JM (2003) Early p53 mutation in nondysplastic Barrett’s tissue detected
by the restriction site mutation (RSM) methodology. Br J Cancer 88:
1217–1276
Klump B, Hsieh C-J, Holzmann K, Gregor M, Porschen R (1998)
Hypermethylation of the CDKN2/p16 promoter during neoplastic
progression in Barrett’s esophagus. Gastroenterology 115: 1381–1386
Kusser WC, Levin DB, Glickman BW (1993) Sensitive two-stage PCR of p53
genomic DNA exons 5–9. PCR Methods Appl 2: 250–252
Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P (2001) Unlocking the
archive – gene expression in paraffin embedded tissue. J Pathol 195: 66–71
Morgan RJ, Newcomb PV, Bailey M, Hardwick RH, Alderson, D (1998) Loss
of heterozygosity at microsatellite marker sites for tumour suppressor
genes in oesophageal adenocarcinoma. Eur J Surg Oncol 24: 23–37
Moskaluk CA, Heitmiller R, Zahurak M, Schwab C, Sidransky D, Hamilton
SR (1996) p53 and p21 (WAF1/CIP1/SDI1) gene products in Barrett’s
esophagus and adenocarcinoma of the esophagus and esophagogastric
junction. Hum Pathol 27: 1211–1220
Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid
BJ (1994) p53 mutations in Barrett’s adenocarcinoma and high-grade
dysplasia. Gastroenterology 106: 1589–1595
Nilsson J, Skobe V, Johansson J, Willen R, Johnsson F (2000) Screening for
oesophageal adenocarcinoma: an evaluation of a surveillance program for
columnar metaplasia of the oesophagus. Scand J Gastroenterol 35: 10–16
Nowell PC (1976) The clonal evolution of tumour cell populations. Science
194: 23–28
O’Connor JB, Falk GW, Richter JE (1999) The incidence of adenocarcinoma
and dysplasia in Barrett’s esophagus – report on the Cleveland Clinic
Barrett’s Esophagus Registry. Am J Gastroenterol 94: 2037–2042
Pillai G, Roberts H, Gatter K, Pezzella F (2003) p53 expression in normal
paraffinembedded tissue using different antibodies and antigen retrieval
buffer systems. Histopathology 42: 83–87
Reno C, Marchuk L, Sciore P, Frank CB, Hart DA (1997) Rapid isolation of
total RNA from small samples of hypocellular, dense connective tissues.
BioTechniques 22: 1082–1086
Rioux-Leclercq N, Turlin B, Sutherland F, Heresbach N, Launois B,
Campion J, Ramee M (1999) Analysis of Ki-67, p53 and bcl-2 expression
in the dysplasia-carcinoma sequence of Barrett’s esophagus. Oncol Rep 6:
877–882
Soslow RA, Altorki NK, Yang GY, Xie D, Yang CS (1999) mdm-2 expression
correlates with wild-type p53 status in esophageal adenocarcinoma. Mod
Pathol 12: 580–586
Tomlinson IPM, Lambros MBK, Roylance RR (2002) Loss of heterozygosity
analysis: practically and conceptually flawed? Genes Chromosomes
Cancer 34: 349–353
Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ (1997) p16 promoter is
hypermethylated at a high frequency in esophageal adenocarcinomas.
Cancer Res 57: 2619–2622
Wu T, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR
(1998) Genetic alterations in Barrett’s esophagus and adenocarcinomas
of the esophagus and esophagogastric junction region. Am J Pathol 153:
287–294
Yoshida T, Mikami T, Mitomi H, Okayasu I (2003) Diverse p53 alterations
in ulcerative colitis-associated low-grade dysplasia: full-length gene
sequencing in microdissected single crypts. J Pathol 199: 166–175
Younes M, Lechago J, Chakraborty S, Ostrowski M, Bridges M, Meriano F,
Solcher D, Barroso A, Whitman D, Schwartz J, Johnson C, Schmulen AC,
Verm R, Balsaver A, Carlson N, Ertant A (2000) Relationship
between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1
overexpression in Barrett’s metaplasia. Scand J Gastroenterol 35:
131–137
Characterisation of p53 status in oesophageal adenocarcinoma
SH Doak et al
1735
British Journal of Cancer (2003) 89(9), 1729–1735 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y